Targeted Treatment for Brain Tumors
Author Information
Author(s): Szereday Z, Schally A V, Nagy A, Plonowski A, Bajo A M, Halmos G, Szepeshazi K, Groot K
Primary Institution: Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center
Hypothesis
Can bombesin analogue AN-215 effectively target and treat glioblastoma in mice?
Conclusion
The study found that AN-215 significantly inhibited the growth of glioblastomas in mice compared to the non-targeted treatment.
Supporting Evidence
- AN-215 treatment extended tumor doubling time from 4.54 days to 8.18 days.
- AN-215 reduced final tumor volume by 69.6% compared to controls.
- AN-215 was shown to bind with high affinity to glioblastoma receptors.
Takeaway
Researchers tested a special medicine that targets brain tumors in mice, and it worked much better than a regular treatment.
Methodology
The study involved injecting mice with glioblastoma cells and treating them with AN-215 to measure tumor growth inhibition.
Potential Biases
Potential bias in the selection of treatment groups and the small sample size.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
Male athymic nude mice, approximately 6 weeks old.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website